E-LIB Suche - Ergebnisse für: Højen, J.F.

1

Sequential Vacc-4x and romidepsin during combination antire..:

Tapia, G. ; Højen, J.F. ; Ökvist, M....
Journal of Infection. 75 (2017) 6 - p. 555-571 , 2017

Link: https://doi.org/10.1016/..

2

Innate DNA sensing is impaired in HIV patients and IFI16 ex..:

Nissen, S K ; Højen, J F ; Andersen, K L D...
Clinical and Experimental Immunology. 177 (2014) 1 - p. 295-309 , 2014

Link: https://doi.org/10.1111/..

3

Impact of a TLR9 agonist and broadly neutralizing antibodie..:

Gunst, Jesper D. ; Højen, Jesper F. ; Pahus, Marie H....
Nature Medicine. 29 (2023) 10 - p. 2547-2558 , 2023

Link: https://doi.org/10.1038/..

4

SARS-CoV-2 elicits robust adaptive immune responses regardl..:

Nielsen, Stine SF ; Vibholm, Line K ; Monrad, Ida...
EBioMedicine. 68 (2021) - p. 103410 , 2021

Link: https://doi.org/10.1016/..

5

SARS-CoV-2 persistence is associated with antigen-specific ..:

Vibholm, Line K. ; Nielsen, Stine S.F. ; Pahus, Marie H....
EBioMedicine. 64 (2021) - p. 103230 , 2021

Link: https://doi.org/10.1016/..

6

cAIMP administration in humanized mice induces a chimerizat..:

Andersen, Anna H. F. ; Olesen, Rikke ; Jønsson, Kasper L....
Immunology. 157 (2019) 2 - p. 163-172 , 2019

Link: https://doi.org/10.1111/..

7

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts..:

Vibholm, Line ; Schleimann, Mariane H. ; Højen, Jesper F....
Clinical Infectious Diseases. 64 (2017) 12 - p. 1686-1695 , 2017

Link: https://www.jstor.org/st..

8

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts..:

Vibholm, Line ; Schleimann, Mariane H. ; Højen, Jesper F....
Clinical Infectious Diseases. 64 (2017) 12 - p. 1686-1695 , 2017

Link: https://doi.org/10.1093/..

9

Combined effect of Vacc-4x, recombinant human granulocyte m..:

Leth, Steffen ; Schleimann, Mariane H ; Nissen, Sara K...
The Lancet HIV. 3 (2016) 10 - p. e463-e472 , 2016

Link: https://doi.org/10.1016/..

10

Interleukin-37 Expression Is Increased in Chronic HIV-1-Inf..:

Højen, Jesper F. ; Rasmussen, Thomas A. ; Andersen, Karen Lise D....
Molecular Medicine. 21 (2015) 1 - p. 337-345 , 2015

Link: https://doi.org/10.2119/..

11

Co-production of a structured integrated post pulmonary emb..:

Hojen, A A ; Lindegaard, S F ; Larsen, T B..
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

12

Impact of a TLR9 agonist and broadly neutralizing antibodie..:

Gunst, Jesper D ; Højen, Jesper F ; Pahus, Marie H...
https://vbn.aau.dk/da/publications/6ad91524-b672-49bf-9014-dbbc60094ffe. , 2023

Link: https://vbn.aau.dk/da/pu..

13

Impact of a TLR9 agonist and broadly neutralizing antibodie..:

Gunst, Jesper D ; Højen, Jesper F ; Pahus, Marie H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579101/. , 2023

Link: http://www.ncbi.nlm.nih...

14

Impact of a TLR9 agonist and broadly neutralizing antibodie..:

Gunst, Jesper D ; Højen, Jesper F ; Pahus, Marie H...
Gunst, Jesper D. Højen, Jesper F. Pahus, Marie H. Rosás-Umbert, Miriam Stiksrud, Birgitte McMahon, James H. Denton, Paul W. Nielsen, Henrik Johansen, Isik S. Benfield, Thomas Leth, Steffen Gerstoft, Jan Østergaard, Lars Schleimann, Mariane H. Olesen, Rikke Støvring, Henrik Vibholm, Line Weis, Nina Dyrhol-Riise, Anne Ma Pedersen, Karen B. H. Lau, Jillian S. Y. Copertino, Dennis C. Linden, Noemi Huynh, Tan T. Ramos, Victor Jones, R. Brad Lewin, Sharon R. Tolstrup, Martin Rasmussen, Thomas A. Nussenzweig, Michel C. Caskey, Marina Reikvam, Dag Henrik Søgaard, Ole S. . Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nature Medicine. 2023, 29(10), 2547-2558. , 2023

Link: http://hdl.handle.net/10..

15

Impact of a TLR9 agonist and broadly neutralizing antibodie..:

Gunst, Jesper D ; Højen, Jesper F ; Pahus, Marie H...
https://pure.au.dk/portal/en/publications/36275b18-109b-4217-a6fc-b06a25bf11c8. , 2023

Link: https://pure.au.dk/porta..